Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives

Environ Sci Pollut Res Int. 2021 Sep;28(36):49447-49466. doi: 10.1007/s11356-021-15759-5. Epub 2021 Aug 5.

Abstract

Cancer, a major public health problem, is one of the world's top leading causes of death. Common treatments for cancer include cytotoxic chemotherapy, surgery, targeted drugs, endocrine therapy, and immunotherapy. However, despite the outstanding achievements in cancer therapies during the last years, resistance to conventional chemotherapeutic agents and new targeted drugs is still the major challenge. In the present review, we explain the different mechanisms involved in cancer therapy and the detailed outlines of cancer drug resistance regarding multidrug resistance-associated proteins (MRPs) and their role in treatment failures by common chemotherapeutic agents. Further, different modulators of MRPs are presented. Finally, we outlined the models used to analyze MRP transporters and proposed a future impact that may set up a base or pave the way for many researchers to investigate the cancer MRP further.

Keywords: ABC transporters; Anticancer drugs; Epigenetic alterations; MDR; MRP; MicroRNAs; Organoids.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Drug Resistance, Neoplasm
  • Forecasting
  • Humans
  • Multidrug Resistance-Associated Proteins / pharmacology
  • Multidrug Resistance-Associated Proteins / therapeutic use
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Multidrug Resistance-Associated Proteins